Syngene International Ltd. · NSE:SYNGENE
Syngene International — Q1 FY26 Earnings Presentation
16 slides from Syngene International's earnings presentation, Jul 24, 2025
Slide 1: Syngene International Q1 FY26 Earnings Call
Syngene Internatio nal Q1 FY26 Earnings Call 24 July 2025 1
Slide 2: Safe Harbor Statement
Safe Harbor Statement Certain statements in this release concerning our future growth prospects are forward-looking statements, which are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those contemplated in such forward-looking s
Slide 3: CEO Remarks
CEO Remarks Peter Bains Managing Director & CEO Syngene International Limited Putting Science to Work 3
Slide 4: Q1 FY26: Financial performance in line with expectations
Q1 FY26: Financial performance in line with expectations Revenue from operations Sales Split INR 875 Cr ( 11% Y-o-Y) ~ 7% increase in constant currency terms Driven by Research services 33% Operating EBITDA & Margin Operating EBITDA INR 206 Cr ( 21% Y- Research o-Y) Services Operating EBITDA Margin
Slide 5: Segment Highlights: Research Services
Segment Highlights: Research Services Successful transition of 20+ Inauguration of a Concluded over pilot programs into new state-of-the- 20 client and longer-term contracts art, dedicated regulatory audits peptide during the laboratory quarter Biotech funding still volatile – we remain agile in our
Slide 6: Segment Highlights: CDMO Services
Segment Highlights: CDMO Services Unit III, SM facility, Bengaluru: Mangaluru: Syngene’s increasing biologics facility capacity utilization became and pipeline operational development Delivered a resilient performance this quarter Bayview facility, US: revalidation and integration on track Putting S
Slide 7: Leadership Appointments
Leadership Appointments Putting Science to Work 7
Slide 8: Leadership Appointments
Leadership Appointments Priyaranjan Patnaik Gaurav Kushwaha Ajay Tandon Vice President, Discovery Biology Chief Technology Officer Head, Strategy & Corporate Development Putting Science to Work 8
Slide 9: #1 in India, Pharma and Biotech sector; Global Top 20
Proud to be recognized by TIME Magazine and Statista as one of the World’s Most Sustainable Companies, 2025 Syngene ranked #1 in India, Pharma and Biotech sector Global Top 20, Pharma and Biotech sector Putting Science Putting to Work Science to Work9
Slide 10: CEO's Concluding Remarks
CEO’s Concluding Remarks We are encouraged by a positive start to the financial year While we remain mindful of ongoing macroeconomic factors, we maintain a confident outlook Putting Science to Work 10
Slide 11: CFO Remarks
CFO Remarks Deepak Jain Chief Financial Officer Syngene International Limited Putting Science to Work 11
Slide 12: Q1 FY26: Positive start to the year with y-o-y growth trajectory
Q1 FY26: Positive start to the year with y-o-y growth trajectory Q1 FY26 Revenue from Operations (INR Cr) 900 875 - %Y 850 +11 790 o-Y Q1 FY26 growth 800 +11% Y-o-Y (reported currency) 750 +7% Y-o-Y (constant currency) 700 • Continued growth momentum in Research 650 Services conversion of pilots in
Slide 13: Costs and Profitability
Costs and Profitability Reported PAT before exceptional items % of Revenue from operations (INR Cr) Q1 Q1 Y-o-Y FY25 FY26 Change 87 Operating EBITDA 22% 24% Margin ~200 bps Y- 9% Raw material cost 30% 25% -7% +5 o-Y 54 Staff cost 32% 33% 15% Other Direct cost 3% 3% 2% Other Expenses 13% 15% 22% Q1 F
Slide 14: Capex summary: USD 8mn invested in Q1 FY26
Capex summary: USD 8mn invested in Q1 FY26 Capex Spend (%) 14% 30% Q1 FY26 56% Research CDMO Others Putting Science to Work 14
Slide 15: Guidance for full year FY26 maintained
Guidance for full year FY26 maintained FY26 Guidance Overall Syngene given Revenue from Ops Mid Single digit Growth Operating EBITDA Margin Mid 20s PAT growth before Negative exceptions Capex (USD Mn) 55 Underlying Revenue Growth Early (ex inventory rebalancing in teens biologics commercial manufact
Slide 16: Q&A
Q&A Putting Science to Putting Science to Work Work
Syngene International — Q1 FY26 Earnings Presentation on 6ix